Results 91 to 100 of about 9,301 (205)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena, Gallo Anna L, D'Avolio Antonio, Tempestilli Massimo, Bellagamba Rita, Tommasi Chiara, Nicastri Emanuele, Pucillo Leopoldo P, Narciso Pasquale   +8 more
doaj   +1 more source

Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile [PDF]

, 2008
Francisco J. Blanco, Miguel Arredondo, Freddy Guevara, Carmen Garrido, Judit Morelló, Sonia Rodrı́guez-Nóvoa, Mònica Córdoba, Juan González‐Lahoz, Vincent Soriano   +8 more
openalex   +1 more source

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts) [PDF]

, 2008
Francesca Gatti, A. Matti, Paola Nasta, Giuliana Cologni, Silvia Costarelli, Giampiero Carosi   +5 more
openalex   +1 more source

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection [PDF]

, 2008
David A. Cooper, Roy T. Steigbigel, José M. Gatell, Jürgen K. Rockstroh, Christine Katlama, Patrick Yéni, Adriano Lazzarin, Bonaventura Clotet, Princy Kumar, Joseph Eron, Mauro Schechter, Martin Markowitz, Mona Loutfy, Jeffrey L. Lennox, Jing Zhao, Joshua Chen, Desmon̄d Ryan, Rand R. Rhodes, John A. Killar, Lucinda R. Gilde, Kim M. Strohmaier, Anne R. Meibohm, Michael D. Miller, Daria J. Hazuda, Michael L. Nessly, Mark J. DiNubile, Robin Isaacs, Hedy Teppler, Bach-Yen Nguyen   +28 more
openalex   +1 more source

Long-term efficacy and safety of raltegravir in the management of HIV infection

Infection and Drug Resistance, 2014
Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC   +4 more
doaj  

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro [PDF]

, 2008
Isabelle Malet, Olivier Delelis, Marc‐Antoine Valantin, Brigitte Montès, Cathia Soulié, Marc Wirden, Luba Tchertanov, Gilles Peytavin, Jacques Reynes, Jean‐François Mouscadet, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin   +12 more
openalex   +1 more source

Abstract Supplement Abstracts from IAS 2025, the 13th IAS Conference on HIV Science, 13 – 17 July, Kigali, Rwanda & Virtual

Journal of the International AIDS Society, Volume 28, Issue S4, July 2025.
wiley   +1 more source

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

Adolescent Health, Medicine and Therapeutics, 2013
Kajal B Larson, Jennifer R King, Edward P Acosta Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA Abstract: Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA,
Larson KB, King JR, Acosta EP
doaj  

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection

Терапевтический архив, 2014
AIM. To evaluate the efficiency and safety of using raltegravir (RAL) twice daily in conjunction with a once-daily fixed dose combination of abacavir (ABC)/lamivudine (3TC) in patients with HIV infection and active tuberculosis who have not previously ...
A V Kravchenko, V N Zimina, A A Popova, M O Deulina, V G Kanestri, É S Ivanova, A A Iakovlev, V V Pokrovskiĭ   +7 more
doaj